Medtronic (MDT) is a publicly traded Neuromodulation & Stimulation company founded in 1949 and based in Dublin, Ireland.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Medtronic reported Q1 FY2027 revenue of $9.756 billion, up 13.7% organically—200 basis points above guidance—though an extra fiscal week contributed ~$570 million. GAAP diluted EPS reached $1.14; non-GAAP EPS was $1.45, ahead of guidance. Cardiovascular led with 18.9% organic growth, driven by Electrophysiology Therapies (15% growth) and Cardiac Ablation Solutions (88%). Neuroscience grew 9.3%, Cranial and Spinal Technologies up 13%; Pelvic Health posted 15% growth from Altaviva technology. Medical Surgical rose 10.2%, with Acute Care Monitoring up 14%. The company completed acquisitions of Scientia Vascular and SPR Therapeutics, announced expanded CE Mark indication for Aferra ablation solutions, and partnered with Cornerstone Robotics for robotic-assisted surgery. Management raised FY2027 organic revenue guidance 50 basis points to 7.25–7.75% and non-GAAP EPS guidance to $5.94–$6.00.
FY2027 organic revenue growth 7.25%–7.75%; diluted non-GAAP EPS $5.94–$6.00
Fully implantable DBS system for Parkinson's disease, essential tremor, and dystonia featuring BrainSense technology — the first FDA-approved DBS device capable of simultaneously delivering stimulation and recording local field potentials. Enables clinicians to personalize therapy using chronic neural data streamed to the Medtronic app.
Rechargeable, MRI-compatible spinal cord stimulator for chronic back and limb pain. Supports Medtronic's AdaptiveStim closed-loop algorithm, which adjusts stimulation amplitude in real time using posture-sensing data from an accelerometer. Commercially deployed globally with tens of thousands of patients.
Next-generation SCS device that reads evoked compound action potentials from the spinal cord and adjusts stimulation output within milliseconds, delivering objective closed-loop pain control. Received FDA approval in 2023, representing Medtronic's most advanced neural-sensing SCS platform to date.
500 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.
No recently verified openings are available right now. The company's careers page has the latest.
View all careers ↗